KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Invested Capital (2016 - 2025)

Historic Invested Capital for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $1.4 billion.

  • Sarepta Therapeutics' Invested Capital fell 4461.72% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 4461.72%. This contributed to the annual value of $2.7 billion for FY2024, which is 2705.96% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Invested Capital stood at $1.4 billion, which was down 4461.72% from $1.4 billion recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Invested Capital high stood at $2.7 billion for Q4 2024, and its period low was $1.0 billion during Q3 2021.
  • For the 5-year period, Sarepta Therapeutics' Invested Capital averaged around $1.7 billion, with its median value being $1.9 billion (2022).
  • As far as peak fluctuations go, Sarepta Therapeutics' Invested Capital soared by 9111.76% in 2022, and later crashed by 4806.84% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Invested Capital stood at $1.5 billion in 2021, then increased by 29.33% to $1.9 billion in 2022, then grew by 8.71% to $2.1 billion in 2023, then grew by 27.06% to $2.7 billion in 2024, then plummeted by 49.11% to $1.4 billion in 2025.
  • Its Invested Capital stands at $1.4 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.1 billion for Q1 2025.